04/22/2024
4:15 PM | Adaptimmune Therapeutics (Filer)
| Form ARS | |
04/12/2024
7:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/11/2024
7:00 AM | Adaptimmune Therapeutics (Filer)
| Form DEF 14A | |
04/02/2024
7:38 PM | Adaptimmune Therapeutics (Subject)
New Enterprise Associates 14, L.P. (Filed by)
| Form SC 13D/A | |
04/01/2024
7:01 AM | Adaptimmune Therapeutics (Filer)
| Form PRE 14A | |
03/26/2024
10:59 AM | Adaptimmune Therapeutics (Subject)
EcoR1 Capital, LLC (Filed by)
| Form SC 13G/A | |
03/26/2024
11:00 AM | Adaptimmune Therapeutics (Issuer)
EcoR1 Capital, LLC (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
|
03/06/2024
6:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/06/2024
6:12 AM | Adaptimmune Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/27/2024
7:13 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/31/2024
4:07 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/30/2024
4:26 PM | Adaptimmune Therapeutics (Subject)
EcoR1 Capital, LLC (Filed by)
| Form SC 13G | |
01/29/2024
10:52 AM | Adaptimmune Therapeutics (Subject)
BAILLIE GIFFORD & CO (Filed by)
| Form SC 13G/A | |
01/17/2024
4:30 PM | Adaptimmune Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:30 PM | Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Bertrand William C JR (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:30 PM | Adaptimmune Therapeutics (Issuer)
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Lunger John (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:31 PM | Adaptimmune Therapeutics (Issuer)
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:31 PM | Adaptimmune Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:31 PM | Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Rawcliffe Adrian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:00 PM | Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:01 PM | Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:01 PM | Adaptimmune Therapeutics (Issuer)
Wood Gavin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:01 PM | Adaptimmune Therapeutics (Issuer)
TAYTON-MARTIN HELEN KATRINA (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:02 PM | Adaptimmune Therapeutics (Issuer)
Brewer Joanna Elizabeth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:02 PM | Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:03 PM | Adaptimmune Therapeutics (Issuer)
Hege Kristen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:03 PM | Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:06 PM | Adaptimmune Therapeutics (Issuer)
Behbahani Ali (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/04/2024
6:46 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/06/2023
6:13 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/08/2023
11:59 AM | Adaptimmune Therapeutics (Subject)
Long Focus Capital Management, LLC (Filed by)
| Form SC 13G | |
11/08/2023
6:37 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/31/2023
7:07 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/01/2023
6:00 PM | Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/31/2023
4:19 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/09/2023
6:42 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/10/2023
4:01 PM | Adaptimmune Therapeutics (Issuer)
Menzel Garry E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/10/2023
3:15 PM | Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
| Form SC 13G/A | |
07/03/2023
4:16 PM | Adaptimmune Therapeutics (Issuer)
Behbahani Ali (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2023
4:00 PM | Adaptimmune Therapeutics (Issuer)
Allen Andrew R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2023
4:01 PM | Adaptimmune Therapeutics (Issuer)
MOTT DAVID M (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
AI finds its first serious application (Ad) AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing.
Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry |
07/03/2023
4:02 PM | Adaptimmune Therapeutics (Issuer)
Alleva Lawrence M (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2023
4:02 PM | Adaptimmune Therapeutics (Issuer)
Sigal Charles Elliott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2023
4:03 PM | Adaptimmune Therapeutics (Issuer)
Menzel Garry E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2023
4:04 PM | Adaptimmune Therapeutics (Issuer)
Furey John (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2023
4:04 PM | Adaptimmune Therapeutics (Issuer)
Hegde Priti (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/29/2023
3:48 PM | Adaptimmune Therapeutics (Filer)
| Form S-8 POS | |
06/29/2023
3:54 PM | Adaptimmune Therapeutics (Filer)
| Form S-8 POS | |
06/29/2023
3:25 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/27/2023
8:15 PM | Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/01/2023
3:09 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/30/2023
3:18 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/30/2023
3:21 PM | Adaptimmune Therapeutics (Filed by)
TCR2 THERAPEUTICS INC. (Subject)
| Form 425 | |
05/22/2023
5:59 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/22/2023
6:01 AM | Adaptimmune Therapeutics (Subject)
| Form 425 | |
05/16/2023
6:35 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/12/2023
6:36 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
